How to include Predose housing in Pro­to­col? [Design Issues]

posted by kvgreddy06 – India, 2014-07-23 20:12 (4360 d 22:50 ago) – Posting: # 13302
Views: 3,509

Dear ALL

We can write like, All subjects will be housed in the clinical study facility at least 24.00 hours before administration of the IP and will continue to remain in the clinical study facility for at least 24.00 hours after administration of the IP in each study period.

pre dose In house will be usefull in few BE studies,
we have experience in this case.

Kind regards
venu

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
283 visitors (0 registered, 283 guests [including 16 identified bots]).
Forum time: 19:03 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5